MarketCap
Iovance Biotherapeutics IOVA
$ 8.7
0.11%
Facebook
X
Telegram
Iovance Biotherapeutics Financial Ratios 2025-2007 | IOVA
Brief overview of Iovance Biotherapeutics's valuation and returns
Ratios are assessed across five available annual reports in the 2021–2025 interval.
The valuation comparison uses EV/EBITDA 0.17x (median 0.57x), P/S 0.01x (median 0.01x), P/B 0x (median 0x). Multiples are on average 45.4% below their own medians. Shares look cheaper than their recent historical valuation.
The latest available business-quality ratios are ROE -56%, ROA -42.8%, ROCE -52.1%. The business is not generating positive returns on invested resources. Valuation should be read cautiously until earnings recover.
Valuation takeaway
Iovance Biotherapeutics's valuation is lower, but weak quality metrics call for caution. Recovery in earnings and capital returns is the key catalyst.
Annual Financial Ratios Iovance Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -14.1 | -6.8 | -10.5 | -7.2 | -9.6 | -16.3 | -2.5 | -2.7 | -3.1 | - | - | - | - |
P/S |
0.0 | 0.0 | 3.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS |
-1.1 | -1.3 | -1.9 | -2.5 | -2.2 | -1.9 | -1.6 | -1.3 | -1.4 | -1.9 | -0.6 | -0.5 | -3.5 | -0.0 | -0.3 | -0.0 | - | - | - |
EV (Enterprise Value) |
52.9 M | 85.9 M | 85 M | -66.2 M | 80.4 M | 51 M | 2.82 B | 778 M | 833 M | 280 M | 234 M | 153 M | 46.4 M | 20.1 M | 92.6 M | -1.29 M | -8.26 K | -2.9 K | - |
EBITDA per Share |
-1.09 K | -1.32 K | -1.91 K | -2.45 K | -2.21 K | -1.89 K | -1.65 | -1.31 | -1.41 | -0.953 | -0.605 | -0.478 | -2.32 | -10.2 | -27.7 | -0.01 | - | - | - |
EV/EBITDA |
-0.1 | -0.2 | -0.2 | 0.2 | -0.2 | -23.2 | -13.5 | -6.0 | -9.0 | -5.2 | -9.4 | -12.7 | -2.0 | -1.7 | -4.0 | 1.7 | 0.6 | - | - |
PEG |
0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.56 | 0.69 | 0.44 | -0.04 | -0.33 | 0.19 | 0.19 | 0.03 | -0.0 | - | - | - | - |
P/B |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.3 | 1.8 | 6.7 | 2.3 | 2.6 | 4.4 | 3.6 | -0.8 | -6.2 | - | - | - | - |
P/CF |
-0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -16.8 | -8.3 | -12.2 | -11.2 | -13.6 | -19.2 | -17.4 | -3.9 | -12.8 | - | - | - | - |
ROE % |
-55.97 | -52.39 | -75.95 | -79.24 | -55.05 | -39.54 | -66.08 | -26.51 | -63.28 | -31.69 | -26.59 | -26.84 | -144.18 | 29.22 | 201.03 | -252.00 | 116.93 | -2570.75 | - |
ROA % |
-42.82 | -40.88 | -56.90 | -59.63 | -44.03 | -33.78 | -57.32 | -25.70 | -59.25 | -30.77 | -26.18 | -25.88 | -127.71 | -11245.43 | -4520.19 | -110.06 | - | - | - |
ROCE % |
-52.06 | -50.16 | -68.74 | -69.67 | -49.80 | -36.71 | -67.70 | -27.50 | -63.84 | -32.13 | -26.78 | -26.85 | -128.61 | 71.85 | 164.76 | -127.79 | 116.93 | - | - |
Current Ratio |
4.3 | 4.6 | 4.0 | 4.0 | 5.0 | 6.9 | 8.1 | 33.0 | 15.1 | 34.1 | 63.8 | 27.1 | 8.7 | 0.0 | 0.0 | - | - | - | - |
DSO |
105.1 | 77.3 | 23.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
108.7 | 121.1 | 1832.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
52.3 | 118.7 | 10551.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
213.9 | 198.4 | 1855.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
161.5 | 79.8 | -8696.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Iovance Biotherapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.11 | -0.19 | -0.25 | -0.33 | -0.36 | - | -0.28 | -0.34 | -0.42 | - | -0.46 | -0.47 | -0.5 | - | -0.63 | -0.63 | -0.58 | - | -0.55 | -0.53 | -0.51 | -0.47 | -0.4 | -0.47 | -0.55 | -0.5 | -0.4 | -0.38 | -0.3 | -0.27 | -0.36 | -0.34 | -0.31 | -0.36 | -0.35 | -0.37 | -0.33 | -0.25 | -1.15 | -0.23 | -0.14 | -0.17 | -0.16 | -0.14 | -0.14 | -0.17 | -0.11 | -0.09 | -0.11 | - | -0.66 | -4.19 | -1.28 | - | -0.86 | - | 7.39 | - | -0.07 | -0.15 | -0.01 |
EBITDA per Share |
-101 | -187 | -236 | -330 | -367 | - | -262 | -347 | -431 | - | -470 | -477 | -0.51 | - | -0.62 | -0.62 | -0.57 | - | -0.54 | -528 | -510 | - | -397 | -474 | -557 | - | -409 | -401 | -322 | - | -361 | -343 | -316 | - | -342 | -370 | -332 | - | -309 | -219 | -139 | - | -0.15 | -0.13 | -0.14 | - | -0.1 | -0.09 | -0.11 | - | -0.66 | -1.25 | -0.86 | - | -2.07 | -2.1 | -4.01 | - | -0.07 | -0.13 | -0.01 |
ROE % |
-46.36 | -55.06 | -54.91 | -54.55 | -55.18 | -40.05 | -56.93 | -64.54 | -68.00 | -51.39 | -76.69 | -80.83 | -79.01 | -62.91 | -75.25 | -60.87 | -51.51 | -34.91 | -45.33 | -41.92 | -40.59 | -39.54 | -50.38 | -58.01 | -64.32 | -66.08 | -51.80 | -42.51 | -33.18 | -26.51 | -37.29 | -45.26 | -54.75 | -63.28 | -54.91 | -80.55 | -71.41 | -61.32 | -59.95 | -26.43 | -25.62 | -26.59 | -28.92 | -28.31 | -26.89 | -26.84 | -69.91 | -82.67 | -83.91 | -78.87 | -72.92 | -16.58 | 53.90 | 59.84 | 105.37 | 185.16 | 186.69 | 135.69 | 45.52 | 85.75 | 4.42 |
ROA % |
-36.10 | -42.94 | -42.83 | -42.82 | -43.50 | -31.49 | -44.83 | -50.47 | -53.42 | -40.43 | -58.68 | -58.40 | -54.72 | -41.70 | -51.24 | -32.99 | -43.05 | -29.98 | -38.88 | -36.11 | -34.78 | -33.78 | -43.32 | -50.06 | -55.66 | -57.32 | -45.65 | -38.33 | -30.91 | -25.70 | -35.57 | -42.79 | -51.46 | -59.25 | -51.74 | -77.17 | -68.85 | -59.54 | -58.33 | -25.87 | -25.17 | -26.18 | -28.27 | -27.52 | -26.03 | -25.88 | -63.22 | -74.00 | -74.73 | -69.87 | -2361.02 | -3426.39 | -23035.42 | -23030.15 | -24053.76 | -23690.68 | -22677.23 | -3050.95 | -1023.61 | -1928.07 | -99.27 |
ROCE % |
-43.40 | -51.34 | -51.36 | -50.89 | -51.23 | -36.87 | -52.42 | -58.68 | -62.01 | -47.04 | -68.55 | -74.11 | -72.34 | -57.31 | -68.59 | -57.36 | -47.12 | -32.43 | -40.69 | -38.32 | -37.97 | -27.10 | -43.99 | -52.15 | -56.32 | -46.39 | -53.91 | -43.75 | -33.09 | -20.01 | -35.36 | -44.06 | -51.68 | -45.92 | -57.29 | -48.96 | -36.95 | -22.60 | -29.94 | -24.76 | -22.83 | -18.63 | -24.88 | -22.24 | -21.09 | -15.99 | -69.44 | -69.04 | -68.34 | -63.30 | -48.92 | 19.07 | 52.63 | 56.63 | 102.12 | 170.37 | 160.98 | 133.27 | 45.49 | 82.63 | 5.15 |
Current Ratio |
5.1 | 4.5 | 4.5 | 4.3 | 4.9 | 4.5 | 4.5 | 4.9 | 4.6 | 4.0 | 4.8 | 4.2 | 5.2 | 4.0 | 3.6 | - | 4.7 | 5.0 | 6.3 | 7.9 | 7.3 | 6.9 | 6.9 | 6.9 | 6.9 | 7.5 | 7.5 | 7.5 | 7.5 | 32.9 | 32.9 | 32.9 | 32.9 | 15.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
84.5 | 94.9 | 85.7 | 99.6 | 129.8 | - | 68.1 | 46.7 | 24.6 | - | 3.2 | 6.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
119.3 | 118.2 | 120.4 | 92.9 | 107.4 | - | 96.2 | 66.1 | 175.9 | - | 198.8 | 216.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
66.6 | 73.7 | 75.0 | 48.7 | 51.4 | - | 75.4 | 67.1 | 369.6 | - | 530.2 | 1396.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 206.1 | 192.5 | 237.1 | - | 164.2 | 112.8 | 200.4 | - | 198.8 | 222.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | 131.1 | 143.8 | 185.8 | - | 88.8 | 45.8 | -169.2 | - | -331.3 | -1173.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Iovance Biotherapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Russia
Israel
Britain
Singapore
USA
China
Japan
Canada